Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Izencitinib was generally well tolerated and its safety data were consistent with expectations, but it failed to achieve its primary endpoint. Here’s more about it.
The new authorization is expected to be the final reassurance for many of those who had hesitated when the vaccine was approved under emergency use only.
The FDA has approved the use of the injectable drug KORSUVA in treating moderate to severe pruritus in adult patients undergoing hemodialysis for chronic kidney disease.
Tyra Biosciences aspires to raise a $100 million IPO, according to its S-1 form filed with the U.S. Securities and Exchange commission late last week.
Novartis reported that its Kymriah failed to hit its primary endpoint in the Phase III BELINDA trial in aggressive B-cell non-Hodgkin lymphoma after relapse or lack of response to first-line treatment.
Roche will apply RNAfix and Shape’s AAVid technology platform to develop next-generation tissue-specific adeno-associated viruses for new gene therapies aimed at these indications.
Shoreline Biosciences was propelled into the proverbial catbird’s seat this summer with two mega-deals, and now plans to double its employee base from 50 to 100 in the coming months.
An oral version of remdesivir is being developed by scientists at the University of California San Diego to combat the SARS-CoV-2 virus early in its infection cycle.
While last flu season saw fears of a “twindemic” go largely unfounded, there are fears that recent lockdowns could also lead to a lack of natural immunity against the flu.
Anti-aging organization SENS Research Foundation sacked Chief Science Officer Aubrey de Grey over concerns he has attempted to influence an investigation of sexual harassment claims filed against him.
Research presented earlier this month discussed a possible link between COVID-19 and long-term cognitive deficits and how it may accelerate the pathology and symptoms of Alzheimer’s disease.
Many expect the full approval will lead to vaccine mandates, as that was one of the obstacles to it for many organizations.